Cefepime Dosing for Enterobacter and Pseudomonas Infections
For Enterobacter and Pseudomonas infections, use cefepime 2 g IV every 8 hours, not the standard every 12-hour dosing, to optimize bacterial killing and reduce mortality.
Standard Dosing Recommendations
FDA-Approved Dosing
The FDA label specifies cefepime 1-2 g IV every 8-12 hours for moderate to severe pneumonia caused by Enterobacter species, with 2 g IV every 8 hours specifically required for Pseudomonas aeruginosa infections 1. For complicated intra-abdominal infections involving these organisms, the approved dose is 2 g IV every 8-12 hours 1.
Guideline-Based Dosing
The IDSA/SIS guidelines for complicated intra-abdominal infections recommend cefepime 2 g every 8-12 hours for adults with normal renal function 2. The 2017 WSES guidelines similarly recommend cefepime 2 g every 8 hours for critically ill patients 3. For hospital-acquired pneumonia, the IDSA/ATS guidelines recommend cefepime 2 g IV every 8 hours 4.
Critical Pharmacodynamic Considerations
Why Every 8 Hours Matters
Cefepime requires time-dependent killing, with optimal bactericidal activity achieved when free drug concentrations remain above the MIC for >60% of the dosing interval 5. In a prospective study of 56 patients with Pseudomonas infections, those achieving fT>MIC ≤60% had a 77.8% failure rate versus 36.2% failure when fT>MIC was >60% (P=0.013) 5. Patients with inadequate exposure were 8.1 times more likely to experience microbiological failure 5.
Mortality Benefit with Higher Dosing
A 2025 retrospective analysis of 111 patients with Pseudomonas bacteremia demonstrated that cefepime 4 g/day (1 g every 6 hours) resulted in 44% mortality compared to only 9% mortality with 6 g/day (2 g every 8 hours), P<0.05 6. Extended-infusion cefepime (2 g over 4 hours every 8 hours) reduced mortality from 20% to 3% (P=0.03) in patients with Pseudomonas bacteremia and pneumonia 7.
Specific Dosing by Clinical Scenario
Pseudomonas aeruginosa Infections
- Pneumonia: 2 g IV every 8 hours 1
- Bacteremia: 2 g IV every 8 hours (consider extended infusion over 3-4 hours) 6, 7
- Complicated intra-abdominal infections: 2 g IV every 8 hours (with metronidazole) 1
- Duration: 10-14 days for pneumonia/bacteremia; 7-10 days for intra-abdominal infections 8
Enterobacter Species Infections
- Standard dosing: 2 g IV every 8-12 hours 2
- For critically ill patients or high MIC (≥4 mg/L): Use 2 g every 8 hours 5, 9
- Duration: 7-10 days for most infections 2
Carbapenem-Resistant Organisms
For carbapenem-resistant Pseudomonas (CRPA) susceptible to cefepime, use 2 g IV every 8-12 hours 8. However, for difficult-to-treat Pseudomonas, consider alternative agents like ceftazidime-avibactam or ceftolozane-tazobactam 8.
Pediatric Dosing
For children with Pseudomonas infections, use 50 mg/kg/dose IV every 8 hours (maximum 2 g/dose) 2, 8. For other Enterobacterales, 50 mg/kg/dose every 12 hours may be adequate 2, 8.
Renal Dose Adjustments
Adjust doses for creatinine clearance ≤60 mL/min 1:
- CrCl 30-60 mL/min: 2 g every 12-24 hours
- CrCl 11-29 mL/min: 2 g every 24 hours
- Hemodialysis: 1 g every 24 hours 10
- CVVH: 2 g every 12 hours 10
Critical Pitfalls to Avoid
MIC Considerations
Cefepime 2 g every 12 hours provides inadequate coverage for organisms with MIC ≥8 mg/L 5, 11. Only 45-65% of patients achieve adequate fT>MIC for pathogens at the upper susceptibility limit (MIC 8 mg/L) with standard dosing 11. For MIC values of 4-8 mg/L, use 2 g every 8 hours or consider extended infusion 5, 9.
Neurotoxicity Risk
In patients with renal impairment (CrCl <30 mL/min), cefepime accumulation can cause non-convulsive status epilepticus with confusion and myoclonus 11. Monitor for neurological symptoms and check trough levels if available, targeting <20 mg/L 11.
Combination Therapy
For severe Pseudomonas infections, particularly in neutropenic patients or those with high mortality risk, consider adding an aminoglycoside for the first 3-5 days 2, 4. However, cefepime monotherapy at appropriate doses is generally adequate for susceptible organisms 5, 7.